Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MitoQ for Cognitive Impairment in Early-Phase Schizophrenia
NCT06191965Phase 3Recruiting
- Sponsor
- McLean Hospital
- Start
- Jun 2024
- Primary completion
- Jan 2027
- Modality
- Orthosteric Ligands
- Countries
- 2
01
Overview
A Phase 3 trial of mitoquinone in schizophrenia spectrum and other psychotic disorders, sponsored by McLean Hospital. Started Jun 2024; status: recruiting.
02
Drugs
mitoquinone
03
Conditions
schizophrenia spectrum and other psychotic disorders
Beyond the preview
Go deeper on NCT06191965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06191965.